The purpose of this study is to evaluate the safety, tolerability, drug levels of BMS-986369 following administration of single ascending oral doses (SAD) in healthy adult participants. The study will also explore the effect of high-fat meal on the single-dose drug level of BMS-986369 in healthy adult participants.
3 Primary · 5 Secondary · Reporting Duration: Up to 336 hours after dose administration
68 Total Participants · 3 Treatment Groups
Primary Treatment: BMS-986369 under fasted conditions, Part 2 Food effect · No Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Age 18 - 55 · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: